You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Rituximab for the first-line treatment of stage III-IV follicular lymphoma

  • Technology appraisal guidance
  • Reference number: TA243
  • Published:  25 January 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Follicular lymphoma - rituximab (review): response to consultee, commentator and public comments on the appraisal consultation document (ACD)

Follicular lymphoma - rituximab (review): response to consultee, commentator and public comments on the appraisal consultation document (ACD) Follicular lymphoma - rituximab (review): response to consultee, commentator and public comments on the appraisal consultation document (ACD)
01 December 2011
(162.35 Kb 47 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 28 November 2011

Back to top